ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that a preclinical ...
But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse. So should ORIC Pharmaceuticals ...
Shares of ORIC stock opened at $7.03 on Thursday. The firm has a market cap of $499.32 million, a price-to-earnings ratio of -3.86 and a beta of 1.25. ORIC Pharmaceuticals has a 52-week low of $6. ...
The inducement grants were approved by ORIC’s Compensation Committee of the Board of Directors, as required by Nasdaq Rule 5635 (c) (4), and were granted as a material inducement to employment in ...
TipRanks on MSN11d
Oric Pharmaceuticals Expands Equity Incentive Plan for GrowthOric Pharmaceuticals ( ($ORIC) ) has provided an announcement. On March 11, 2025, Oric Pharmaceuticals’ Board of Directors approved an amendment ...
In other ORIC Pharmaceuticals news, CEO Jacob Chacko sold 24,660 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of ...
ORIC Pharmaceuticals SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing ...
(MENAFN- GlobeNewsWire - Nasdaq) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused ...
(RTTNews) - ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical-stage oncology company, announced its refined registrational clinical development plans for its lead programs, ORIC-944 and ORIC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback